Arterial stiffness is an important risk factor for cardiovascular disease (CVD) in patients with end-stage renal failure. However, little is known about the factors that contribute to arterial rigidity in peritoneal dialysis (PD) patients. The aim of this study was to define the pattern and determinants of the longitudinal change in arterial stiffness after PD initiation.
A rterial stiffness is an important risk factor for cardiovascular disease (CVD) in patients with endstage kidney disease (ESKD). 1) Multiple factors contribute to the stiffening process, including hemodynamics, nutrition, and inflammation. 2) Early recognition and modification of specific factors that rigidify arteries help prevent CVD. Non-invasive vascular testing, pulse wave velocity (PWV), and carotid intima-media thickness (cIMT) are increasingly used as surrogate biomarkers of CVD. 3) PWV is the most widely used measure of arterial stiffening in patients at higher CVD risk. 4) The advantage of PWV is its ability to reflect reversible, functional vascular rigidity, and thereby serve as a marker of therapeutic responsiveness. 5) On the other hand, cIMT represents a morphological change that reflects not only early atherosclerosis, but also non-atherosclerotic remodeling with medial hypertrophy. An increase in cIMT is a predictive marker of CVD. 6) Many studies in CKD and ESKD patients have demonstrated that increased PWV and cIMT are associated with an increased incidence of CVD. 7) In hemodialysis patients, raised PWV predicts both CVDrelated and overall mortality. However, relatively few studies have evaluated the utility of arterial stiffness in patients on peritoneal dialysis (PD). Arterial stiffness in PD patients correlated with the increase in body fluid volume or peritoneal transport rate 8, 9) and was an independent predictor of cardiovascular events. 10) The aim of this study was to define the determinants Nakahigashi, ET AL increased baPWV n = 10 cross-sec onal only n = 23 subanalysis of arterial stiffening in PD patients, particularly in the first two years after initiation of PD by means of cIMT and brachial-ankle PWV (baPWV). BaPWV involves determining the velocity of pulse propagation between the brachial and ankle that reflects vascular stiffness of both peripheral muscular conduit arteries and central elastic, capacitive vessels. 11) In PD patients, there are relatively limited data on baPWV compared with data on carotidfemoral PWV (cfPWV), a well-established index of central arterial stiffness. 12) However, baPWV has several advantages for risk assessment. First, baPWV can be performed easily and routinely as it only requires wrapping the four extremities with blood pressure cuffs. 13) Second, there is ample reference data for baPWV from previous epidemiological studies. 14) Third, baPWV is better for evaluating the rigidity of muscular-type arteries in addition to that of central elastic arteries. Fourth, previous studies on populations at higher risk of CVD have demonstrated that elevated baPWV predicts not only vascular damage (e.g., micro-albuminuria), but also disease end points such as coronary events and stroke. 11) Our multivariate analyses showed that baPWV correlated positively with urinary protein excretion, systolic blood pressure (BP), and plasma glucose. We first demonstrated that baPWV showed a temporal attenuation in accordance with the concomitant decline of BP over the first PD years. Hemodynamic factors had the greatest impact on baPWV, while metabolic milieu (i.e., glucose and/or malnutrition) also contributed to increasing baPWV. In contrast, cIMT was correlated distinctive factors of smoking and hypoalbuminemia, suggesting an essential role of endothelial dysfunction in cIMT changes after starting PD.
Methods

Subjects and biochemical analysis:
This was a prospective, cross-sectional, single-center study. Forty-six PD patients (26 male, 20 female, mean age 55 years) who visited our hospital between January 2009 and March 2013 were enrolled ( Figure 1 , Table I ). The study protocol was reviewed and approved by the Ethics Committee of Kansai Medical University.
The duration of PD was 24.6 months (range, 2-87 months). The patients were treated using either an automated device (APD, 45%), or continuous ambulatory peritoneal dialysis (CAPD, 55%). Standard, neutral 1.25% glucose-based or/and icodextrin (Baxter Healthcare, Tokyo, Japan) dialysates were used. Plasma glucose was measured at arbitrary time on clinical visit. The adequacy of dialysis (Kt/V) was calculated using a singlecompartment model. Trans-peritoneal solute transport rate between dialysate and plasma (D/P) was estimated by a 4hour equilibration test. Measurement of baPWV: BaPWV was measured using an automatic oscillometry device (BP203RPE II, Omron Colin) before and every six months after initiating PD. After a 5-minute rest in the supine position, cuffs were ARTERIAL STIFFNESS IN PD PATIENTS applied onto both arms and ankles. Pulse pressure waveforms of the brachial and tibial arteries were captured simultaneously, followed by measurement of the time interval between the initial peaks of these waveforms (Tba). The PWV was calculated according to the previous literature. 13, 15) Patients with an ankle-brachial index (ABI) < 0.9 were excluded from further evaluations. Measurement of cIMT: cIMT was measured by B-mode ultrasonography using a 5 MHz linear transducer (a10 color Doppler system, Aloka). The thickness of the carotid artery walls was measured on straight longitudinal 10 mm segments of the common carotid artery at positions 2-3 cm apart from the carotid bulb. 6, 16) The thickness was evaluated in arterial segments free of plaques and was defined as the distance between the leading edge of the most internal echogenic line (lumen-intima interface) and the second echogenic line (media-adventitia interface).
Measurement of body fluid volume:
Multi-frequency segmental bioelectrical impedance was measured by using the InBody 720. 17) To estimate a body fluid volume accurately, extracellular water (ECW) was corrected by total body water (TBW), yielding the ratio of ECW/TBW. Statistical analysis: Comparison between two independent groups was performed with un-paired Student's t-test. A pair-wise correlation between continuous variables was analyzed by Pearson's correlation test. Uni-and multivariate analyses were performed by SPSS version 20.0 (IBM, Armonk, NY).
Results
Characteristics of PD patients:
A total of 46 patients were studied, of whom 37% had diabetes mellitus (Table I and Table II ). The vast majority (44 of 46) had hypertension and were taking anti-hypertensive medication. Hemoglobin levels were controlled to a mean of 10.6 g/dL with most patients (96%) being treated with erythropoiesis stimulating agents (Table I) . Mean glucose and serum lipid levels remained within the recommended ranges of hemoglobin A1c (HbA1c) 5.8% and LDL cholesterol 101.4 mg/dL. With regards to the morbidity and mortality during the observational period, three patients manifested the myocardial infarction but eventually recovered from it by medical and/or coronary intervention therapy. The other three individuals died from the septic shock, dissecting aneurysm, and constrictive pericarditis.
Cross-sectional covariates of PWV and cIMT:
A series of measurements of baPWV and cIMT were obtained at subsequent arbitrary time-points (every 6 months for baPWV, and every 12 or 24 months for cIMT) ( Figure 2 ). Univariate analysis showed that baPWV was associated with plasma glucose (r = 0.57, P < 0.001), HbA1c (r = 0.56, P < 0.001), hypoalbuminemia (r = -0.53, P < 0.001), and urinary protein excretion (r = 0.53, P < 0.001) (Table III) . There was also a modest but significant association between baPWV and increases in glycoalbumin (r = 0.45, P = 0.003), pulse pressure (r = 0.42, P = 0.004), systolic BP (r = 0.37, P = 0.01), and age (r = 0.34, P = 0.02), as well as lower LDL cholesterol (r = -0.35, P = 0.02). However, the baPWV values did not correlate with cIMT or body-fluid overload (ECW/TBW, Table III ). The PD-related parameters including adequacy of dialysis (Kt/ V), kidney reserve, and peritoneal transport rate (D/P) did not show any association with baPWV (data not shown).
In contrast, cIMT showed a strong association with Brinkman index (cumulative cigarette consumption, r = 0.71, P < 0.001), diastolic BP (r = -0.59, P = 0.001) and mean arterial pressure (r = -0.56, P = 0.001) (Table III) . Hypoalbuminemia (r = -0.53, P = 0.003), high sensitivity C-reactive protein (hsCRP; r = 0.52, P = 0.004), and lower systolic BP (r = -0.50, P = 0.005) showed a significant but slightly weaker univariate association with cIMT. In addition to age (r = 0.46, P = 0.01), other PD-related Nakahigashi, ET AL Data are shown as mean ± SD with ranges (numbers in parenthesis). PTH indicates parathyroid hormone; hsCRP, high-sensitivity C-reactive protein; hANP, human atrial natriuretic peptide; and NT-proBNP, N-terminal probrain natriuretic peptide. *Hemoglobin A1c was indicated in a NGSP scale (normal range 4.6 to 6.2%). parameters, including phosphorus (r = -0.45, P = 0.01), calcium (r = 0.44, P = 0.02), and Ca × P (r = -0.39, P = 0.04) showed a weak correlation with cIMT (Table III) . Similar to baPWV values, PD duration, adequacy, solute transport rate (D/P), body-fluid volume (ECW/TBW), and residual kidney function did not have any significant influence on cIMT.
Given that CV risk factors in the elderly are usually multifactorial and mutually related, we next analyzed the correlation between the arterial markers in multivariate models. These analyses demonstrated that baPWV was associated independently with urinary protein excretion (r 2 = 0.71, P < 0.001), age (r 2 = 0.71, P < 0.001), systolic BP (r 2 = 0.71, P = 0.001), and HbA1c (r 2 = 0.71, P = 0.003), even after adjustment for serum albumin and LDL cholesterol (Table IV) . Notably, the correlations with cIMT were distinct from those of baPWV, with Brinkman index (r 2 = 0.59, P = 0.004) and hypoalbuminemia (r 2 = 0.59, P = 0.04), showing significant correlation after adjustment for hsCRP and diastolic pressure (Table IV) . The presence of distinctive correlates for cIMT, smoking and hypoalbuminemia, suggested that cIMT may reflect physiological processes slightly different from those involved in baPWV.
To define the role of glycemic control, we conducted a sub-analysis by dividing the patients into two groups of non-diabetes mellitus (DM) and DM ( Figure 3) . The results indicated that the DM group had a higher baPWV than the non-DM group (1973 versus 1638 cm/second, P = 0.009). On the other hand, cIMT values did not differ between the non-DM and DM subgroups (0.94 versus 0.79 mm). These results indicated that hemodynamic con-ditions are critical determinants of both baPWV and cIMT in PD patients. The association of baPWV with HbA1c and glycoalbumin suggested that multiple factors including hyperglycemia could affect arterial stiffness. Longitudinal correlates of ΔbaPWV: We next carried out a prospective investigation of the clinical covariates involved in changes in baPWV (ΔbaPWV) over the twoyear after PD initiation. The baPWV values reduced during the first year of PD (mean 1691 to 1627 cm/second) but did not reach statistical significance (data not shown). Conversely, there was an overall tendency for a subtle increment in baPWV during the second year of PD year (mean 1627 to 1728 cm/second). We next examined the longitudinal relationship between ΔbaPWV and three representative correlates, BP, body fluid status, and plasma glucose. In the univariate analysis, ΔbaPWV showed a positive correlation with changes in systolic BP (Δ systolic BP) in both first and second years after PD initiation (r = 0.72, P < 0.001 versus r = 0.70, P = 0.001 (Figure 4 A). Similarly, Δ diastolic BP correlated positively with ΔbaPWV in both first and second years, albeit to a lesser degree than Δ systolic BP, (r = 0.53, P = 0.009 versus r = 0.66, P = 0.002) ( Figure 4B ). These results indicated that Δ systolic BP had a stronger impact on ΔbaPWV than Δ diastolic BP. Multivariate analysis showed that Δ systolic BP was the only independent determinant of ΔbaPWV between pre-PD and the first PD year (r 2 = 0.49, P < 0.001, n = 23) (Table V) . Further analysis comparing the data between the first and second PD year showed that Δ systolic BP (r 2 = 0.59, P = 0.02, n = 19) still remained an independent determinant of ΔbaPWV, although the correlation became weaker during the second PD year (Table V) . second PD year visits rst PD year visits Changes in markers for body fluid status (i.e., ΔhANP, Δ body weight, and ΔECW/TBW) had no significant influence on baPWV values (data not shown). These results suggest that the observed Δ systolic BP may affect ΔbaPWV through mechanisms other than volume expansion. Notably, HbA1c levels did not show a clear relationship with ΔbaPWV during the first and second PD years ( Figure 4C) .
In order to further delineate the longitudinal relationship between BP and baPWV, we categorized the patients by dividing 23 patients into two subgroups, depending on the baPWV changes over time, either becoming higher or lower. Thirteen patients had a decreasing baPWV value during the first year of PD (P < 0.001) ( Figure 1) . In all but one patient in this decreasing PWV group (12 in 13), both systolic and diastolic BP became lower in accordance with the decline in ΔbaPWV (P < 0.001) ( Figure 5 A-C). Despite the close relationship between baPWV and hemodynamic factors, ΔbaPWV did not correlate with HbA1c levels ( Figure 5D ). These data indicated the arterial rigidity-lowering effects are mainly related to the reduction of BP, rather than those of plasma glucose levels, particularly in the first year after starting PD.
Discussion
This is, to our knowledge, the first longitudinal study that clarifies the clinical correlates of baPWV overtime after initiation of PD. We chose a baPWV because of its technical simplicity only requires attaching an easy-to-use blood pressure cuff onto foot and arms and accumulating evidence for usefulness. 11, 13) Most previous studies employed the femoral and heart (hfPWV) 18) or carotid (cfPWV), a well-established index of central arterial stiffness. [19] [20] [21] The cfPWV measures stiffness from the aorta to iliofemoral axes, while baPWV reflects one in not only central elastic arteries but also peripheral muscular arteries. Our 2-year follow-up observations indicated that BP is a prime determinant of baPWV: nearly half of our patients had a decreasing baPWV during the first PD year. Importantly, nearly all patients in this lowering baPWV subgroup showed a concomitant decrease in both systolic and diastolic BP after initiation of PD. Our study for the first time revealed that there is an overall decreasing ten-Nakahigashi, ET AL Correlations were shown with co-efficient (r) and P values (P) by use of Pearson's formula. LVM indicates left ventricular mass; LVEF, left ventricular ejection fraction; PTH, parathyroid hormone; hsCRP, high-sensitivity C-reactive protein; hANP, human atrial natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; baPWV, brachialankle pulse wave velocity; cIMT, carotid intima-media thickness; and ECW/TBW, extracellular water/total body water. *P < 0.05, **P < 0.005. dency in PWV over the first PD year. The stiffnesslowering effects have been missed in previous longitudinal studies, [18] [19] [20] [21] because the PWV was measured at two arbitrary time points in the maintenance phase when approximately 6 months passed after initiating PD. Then, we found that baPWV exhibited a trend of increasing over the second PD year in parallel with the gradual rise in BP. Notably, we did not see any correlation between changes in baPWV and HbA1c or body-fluid overload (ΔECW/ TBW) during PD, consistent with the observations by others. [18] [19] [20] [21] Moreover, there was no relationship between changes in baPWV and serum calcium and phosphorus levels. These results together suggested that BP control is the first-line approach to retard or even reverse vascular stiffness in the first few years after introducing PD. From a cross-sectional point of view, 8, 9) volume overload has been reportedly shown to associate with cfPWV.
However, we did not find any relationship between baPWV and body-fluid overload cross-sectionally. This disparity might be due to the variability in peritoneal functions among the patients. One previous study demonstrated that both body-fluid overload (higher ECW/TBW) and faster solute transport (higher D/P) were independent determinants of higher cfPWV. 9) This suggests that these patients might be prone to develop volume overloaded partly because of the greater transmesothelial loss of osmotic agents, thereby losing the driving force sufficient for body fluid removal. In this context, our patients preserved an average level of peritoneal solute transport rate (mean D/P = 0.66), which allowed them to maintain nearly normovolemia (mean ECW/TBW 0.40). Alternatively, the discrepant observations may be ascribed to the methodological reason: baPWV measures the stiffness in both muscular conduit vessels and central elastic capaci-ARTERIAL STIFFNESS IN PD PATIENTS Independent determinants for greater baPWV were assessed by multi-variate analyses with adjustment of serum albumin and LDL cholesterol. The adjusted r 2 was 0.71. Independent determinants for higher cIMT was assessed by multi-variate analyses with adjustments of hsCRP and diastolic blood pressure. The adjusted r 2 was 0.59. Brinkman index was calculated by multiplying numbers of daily cigarette consumption and smoking duration (years). baPWV indicates brachial-ankle pulse wave velocity; cIMT, carotid intima-media thickness; and hsCRP, high-sensitivity C-reactive protein.
tive arteries, while cfPWV mostly reflected central arterial rigidity. 22) The other important point in our cross-sectional analysis is that proteinuria was associated independently with faster baPWV in our PD patients. To our knowledge, proteinuria has not yet been previously reported as covariates of baPWV in PD patients. Vascular stiffness is shown to correlate with proteinuria in hypertensive and hyperglycemic patients. 11) It is therefore speculated that microvascular endothelial damage (proteinuria) and functional arterial stiffness (PWV) may share similar pathogenic mechanisms.
As consistent with our observations, most previous studies with assessment of arterial stiffness in either PD or HD patients failed to see any positive correlation between LDL and PWV values. 23) We consider that this lack of correlation may reflect the general tendency towards lower cholesterol levels in ESRD individuals. The dyslipidemia is probably thought to arise from the malnutrition and chronic inflammation, the major consequence of chronic uremic status, 7) but not from the difference in the dialysis modality. In fact, our PD patients showed, on average, normal LDL cholesterol (101.4 mg/dL) and slightly low serum albumin levels (3.4 g/dL). Because of the uremiarelated lower LDL state, it appears that the blood pressure and glycemic levels are more relevantly associated with arterial stiffness than LDL levels, particularly in the earlier period after PD or HD introduction. Further study with larger cohort and longer follow-up is warranted to assess the role of dyslipidemia in progression of arterial stiffening.
We found different clinical determinants existed for baPWV and cIMT. Higher baPWV correlated positively with hyperglycemia and proteinuria, in addition to elevated systolic BP, whereas increased cIMT was associated with smoking and hypoalbuminemia. In our crosssectional analysis (Table IV) , hyperglycemia contributed to baPWV but not cIMT. One possibility of the distinctive determinants for baPWV and cIMT could be ascribed to the different anatomic and physiological properties of arterial trees. Arterial stiffness results from complex interactions involving distensibility, compliance, and elastic modulus. Such properties are not uniform along the arterial tree. The baPWV measures stiffness, not only in the central elastic portion, but also in peripheral musculartype artery. The latter contains more abundant vascular smooth muscle cells. The baPWV in smaller caliber arteries may therefore be susceptible to even subtle delay, distorted microcirculation, or metabolic imbalances (i.e., high glucose levels). We therefore speculate that hypertension and hyperglycemia could accelerate the stiffness through mutually related, complementary mechanisms. Our multivariate analyses demonstrated that increased cIMT of PD patients correlated with smoking and hypoalbuminemia. Cigarette smoking is widely accepted as a major risk factor for the development of CVD. It is thought that smoking induces an oxidative stress to activate the endothelial injury through accumulation of the macrophages and platelets. 24) This process is mediated by suppression of nitric oxide synthesis. Importantly, hypoalbuminemia was found to be as another independent correlate of cIMT. Relationship of low serum albumin and cIMT are in good agreement with previous observations that hypoalbuminemia was associated with inflammation and increased oxidative stress, the process which have been reported as major factors promoting arterial rigidity in dialysis patients. 25) Since PD patients are prone to transperitoneal albumin loses and high-glucose dialysis exposure, there may be a complex association of endothelial dysfunction, inflammation, and hypoalbuminemia, each of which may mutually coactivate the atherogenic process. Further study is required to clarify to which extent these factors contribute to the CVD incidence on PD patients.
Several studies have assessed the impact of dialysis modality on the arterial stiffness. One previous study reported that, despite the similar stiffness levels (cfPWV) before dialysis between the two groups, PWVs for the HD patients are significantly higher than those for PD patients, when evaluated at one year after introduction of dialysis. 26) These results suggest less arterial damage in patients on PD than in patients on HD. Another study also confirmed that baPWV is higher in HD than in PD. 27) However, there are still some contradicting reports that failed to see any differences of PWV between PD and HD. 28) We consider that the conflicting results among these studies may reflect the differences in a) the way of PWV measurement (cfPWV vs baPWV), b) follow-up periods (short versus long term), and patient characteristics (age, duration dialysis, dialysis efficiency, control status of the background medical disorders, etc.). To further evaluate which dialysis modality is beneficial for the prevention of arterial stiffening, we will need to design the longitudinal study with larger number of the patients, which allows better comparison for the two subgroups (HD versus PD).
Because of the relatively small sample size in our study we may have missed some confounding variables that cause rigidification of arteries in PD patients. For instance, we did not see any association between stiffness and variables related to bone mineral metabolism. The role of calcification in the progression of arterial stiffness has been raised as a critical research question by KDIGO. 29) Arterial calcification usually develops in the intima or the media of muscular-type arteries, 30, 31) and may take more time to manifest clinically. Diabetic microangiopathy also progresses at a much slower rate. PD modality may influence arterial rigidity and therefore it is important to compare the effects of volume, exchange methods (APD or CAPD), and contents of dialysates (glucose-based versus icodextrin).
In conclusion, our study demonstrated that baPWV is a useful clinical tool that could help earlier recognition and intervention of arterial stiffness in PD patients. BaPWV is associated with multiple but modifiable variables including BP, hyperglycemia, and proteinuria. It may therefore represent cumulative vascular risk derived from both hemodynamic and metabolic abnormalities. Optimization of BP as well as nutritional conditions (e.g., glucose and albumin levels) will be primary measure for ameliorating arterial stiffness during the initial stage of PD therapy. A large prospective study over a longer period will provide a broader scope of CVD risk in PD patients.
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